Hope S. Rugo, MD, FASCO - Stay in the Know About HER2-Low: Improving Breast Cancer Outcomes with Emerging Antibody Drug Conjugates

Please visit answersincme.com/PHE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in breast oncology discusses the significant of HER2 in the targeted treatment of advanced breast cancer. Upon completion of this activity, participants should be better able to: Identify optimal strategies to assess HER2-low expression in both primary and recurrent tumors in patients with breast cancer; Describe the clinical significance of the latest safety and efficacy data for HER2-targeted antibody drug conjugates in the treatment of patients with HER2-low advanced breast cancer; and Predict the role that HER2-targeted antibody drug conjugates might play in the treatment of pretreated patients with HER2-low advanced breast cancer.

There are no comments yet.

Please log in to write the first comment.